In the right high-risk liver, enhancement kinetics can establish HCC without a biopsy.
Primary diagnostic imageArterial phase hyperenhancement followed by washout is the central noninvasive imaging pattern of HCC in an at-risk liver.Zhenyu Pan, Guozi Yang, Tingting Yuan, Lihua Dong, Lihua Dong / Wikimedia Commons (CC BY 4.0). SourceCC BY 4.0
Select evidence-based HCC surveillance for cirrhosis and chronic hepatitis B risk groups.
Interpret arterial phase hyperenhancement, washout, lesion size, and AFP without overcalling a diagnosis.
Link tumor burden, liver reserve, and performance status to resection, ablation, transplant, locoregional therapy, or systemic therapy.
Mass workup
Characterize before sampling
The figure separates morphology, enhancement, spread, and the decision to obtain tissue.
Quick check
A 58-year-old man with compensated hepatitis C cirrhosis has a new 2.2 cm lesion with nonrim arterial phase hyperenhancement and washout on portal venous imaging.
What is the most appropriate diagnostic interpretation?
Reason it through
Is this patient in a validated at-risk group?Yes; cirrhosis is the principal population for noninvasive imaging diagnosis.
What vascular switch is visible?The lesion recruits arterial supply and becomes relatively hypoenhancing later, producing washout.
Is AFP needed to complete the imaging diagnosis?No; AFP is an imperfect adjunct and is not required when diagnostic imaging criteria are met.
At-risk liver plus arterial hyperenhancement plus washout equals HCC until the staging workup says otherwise.
Recall what AFP can and cannot do
AFP is useful only when its limitations remain visible.
Many early HCCs have normal AFP, while pregnancy, germ cell tumors, and active hepatic inflammation can elevate AFP without HCC.
A rising or markedly abnormal AFP during surveillance warrants diagnostic evaluation even when ultrasound is unrevealing, but AFP alone does not establish HCC.
AFP can contribute prognostic and transplant-selection information in established HCC, yet cross-sectional imaging remains central.
Choose the valid AFP statement.
Normal AFP is not an all-clear signal.
Separate risk, surveillance, diagnosis, and staging
These four decisions use different inputs and should not be collapsed into one AFP value.
Cirrhosis of any cause is the dominant HCC risk state; chronic HBV can produce HCC without cirrhosis, so surveillance depends on demographic, family-history, and validated risk criteria.
Surveillance seeks an early lesion in an asymptomatic high-risk population; diagnostic multiphasic imaging characterizes a detected lesion.
Barcelona Clinic Liver Cancer staging integrates tumor number and size, macrovascular invasion or metastasis, Child-Pugh liver reserve, portal hypertension, and performance status to link stage with treatment.
Compare the role of each clinical layer.
Identifies cirrhosis and selected chronic HBV patients who benefit from surveillance.
Ultrasound plus AFP about every 6 months, with MRI or CT alternatives when ultrasound is inadequate.
Multiphasic CT or contrast MRI applies size-dependent arterial enhancement and washout criteria in at-risk patients.
Combines tumor extent, liver function, and performance status to select treatment.
AFP can assist surveillance, but it cannot substitute for imaging diagnosis or stage.
Map arterialization, washout, and spread
HCC evolves from portal-dominant liver tissue toward abnormal arterial supply.
Washout is relative hypoenhancement on portal venous or delayed phases; an enhancing capsule is another major imaging feature in appropriate size categories.
Tumor in vein, especially portal vein invasion, changes stage and generally removes surgical or transplant options unless an expert pathway says otherwise.
Place each imaging clue in its diagnostic or staging role.
Start at the first landmark.
Use practical thresholds without losing clinical context
Size thresholds organize surveillance, imaging diagnosis, ablation, and transplant evaluation.
Surveillance is generally performed every 6 months; a lesion under 1 cm on ultrasound is usually rechecked with short-interval surveillance because CT or MRI characterization is less reliable at that size.
For a suspicious lesion at least 1 cm, multiphasic CT or MRI is the diagnostic next step in an at-risk patient.
Milan transplant criteria classically include one tumor no larger than 5 cm or up to three tumors each no larger than 3 cm, without macrovascular invasion or extrahepatic spread; downstaging pathways may extend access in selected patients.
Arrange these thresholds from surveillance to advanced treatment pressure.
Thresholds open pathways; liver reserve and tumor biology choose the lane.
Follow the HCC pathway from risk to treatment
A disciplined sequence prevents both delayed diagnosis and premature therapy.
Adults with cirrhosis and appropriate chronic HBV risk profiles undergo semiannual surveillance; subcentimeter ultrasound lesions are generally followed at shorter intervals rather than immediately labeled HCC.
A suspicious lesion at least 1 cm or an abnormal surveillance result prompts multiphasic CT or MRI.
Once HCC is established, stage with high-quality liver imaging, chest imaging as appropriate, laboratory assessment, liver reserve, portal hypertension, and multidisciplinary review.
Order the major decisions.
Identify an at-risk patient
Confirm cirrhosis or a chronic HBV risk profile that warrants surveillance.
Perform surveillance
Use ultrasound and AFP approximately every 6 months; choose alternative imaging if visualization is limited.
Characterize a positive result
Obtain multiphasic CT or MRI and apply standardized imaging criteria.
Stage the whole patient
Measure tumor burden, vascular or extrahepatic spread, liver function, portal hypertension, and performance status.
Select stage-linked therapy
Offer curative therapy when feasible; otherwise choose locoregional or systemic treatment according to stage and liver reserve.
Reveal treatment from tumor burden and liver reserve
The same tumor size can lead to different therapy when portal hypertension or decompensation is disclosed.
Resection is favored for localized HCC in a patient with preserved liver function and adequate future liver remnant, especially without clinically significant portal hypertension.
Thermal ablation is a curative option for selected early tumors, with best local control in small lesions when location permits safe margins.
Transplant treats both tumor and cirrhotic field in eligible early-stage disease; bridging locoregional therapy can limit progression while awaiting transplant.
For advanced Child-Pugh A disease with good performance status, current first-line options include atezolizumab plus bevacizumab after bleeding-risk assessment, a single tremelimumab priming dose followed by durvalumab maintenance, or four nivolumab plus ipilimumab induction doses followed by nivolumab maintenance; contraindications and prior therapy guide sequencing.
Reveal the treatment implication behind each hidden variable.
Solitary tumor, preserved function, no major portal hypertension
Evaluate for surgical resection.
Anatomic feasibility and future liver remnant still matter.
Small early tumor, surgery unsuitable
Use thermal ablation when location permits an adequate margin.
Radiation segmentectomy is an alternative in selected cases.
Early HCC plus decompensated cirrhosis
Evaluate for liver transplantation.
Eligibility includes tumor biology and transplant criteria.
Multifocal liver-limited disease with preserved function
Consider transarterial locoregional therapy.
Do not persist with ineffective embolization when systemic therapy is more appropriate.
Macrovascular invasion or extrahepatic spread
Use systemic therapy when liver function and performance status permit.
Modern first-line therapy usually uses immunotherapy-based combinations after contraindication review.
Workup gate
Choose the next characterization step
Identify what is still unknown before ordering another test or biopsy.
What is the most appropriate diagnostic interpretation?
Key finding. A 58-year-old man with compensated hepatitis C cirrhosis has a new 2.2 cm lesion with nonrim arterial phase hyperenhancement and washout on portal venous imaging.
Answer. Imaging diagnosis of HCC in an at-risk patient
Why. A lesion at least 1 cm with characteristic arterial hyperenhancement and washout on multiphasic CT or MRI can establish HCC noninvasively in an at-risk patient.
Board rule. At-risk liver plus arterial hyperenhancement plus washout equals HCC until the staging workup says otherwise.
Stage 1 of 3: Overview
Overview
Hepatocellular Carcinoma
A disciplined sequence prevents both delayed diagnosis and premature therapy.
Step by step
Follow the HCC pathway from risk to treatment
1Identify an at-risk patientConfirm cirrhosis or a chronic HBV risk profile that warrants surveillance.
2Perform surveillanceUse ultrasound and AFP approximately every 6 months; choose alternative imaging if visualization is limited.
3Characterize a positive resultObtain multiphasic CT or MRI and apply standardized imaging criteria.
4Stage the whole patientMeasure tumor burden, vascular or extrahepatic spread, liver function, portal hypertension, and performance status.
5Select stage-linked therapyOffer curative therapy when feasible; otherwise choose locoregional or systemic treatment according to stage and liver reserve.
Clinical takeaway
Why it mattersOnce HCC is established, stage with high-quality liver imaging, chest imaging as appropriate, laboratory assessment, liver reserve, portal hypertension, and multidisciplinary review.
RememberAt-risk liver plus arterial hyperenhancement plus washout equals HCC until the staging workup says otherwise.
Plan the diagnostic workup
At multidisciplinary tumor board, match each HCC presentation to the next diagnostic or therapeutic move.
Cross out tests that answer the wrong question and highlight what remains unknown. Each case practices the order of workup.
A 62-year-old woman with compensated NASH cirrhosis asks how she should be screened for HCC. Prior ultrasound visualization was adequate.
Which surveillance plan is recommended?
Reason it through
Does her etiology matter once cirrhosis is present?No; cirrhosis from NASH is itself a surveillance indication.
What interval balances tumor growth and burden?Approximately every 6 months.
What two tests are paired when ultrasound is adequate?Liver ultrasound and serum AFP.
Cirrhosis means semiannual surveillance, even when the patient feels well.
Does her etiology matter once cirrhosis is present?What interval balances tumor growth and burden?
Does her etiology matter once cirrhosis is present?No; cirrhosis from NASH is itself a surveillance indication.
What interval balances tumor growth and burden?Approximately every 6 months.
What two tests are paired when ultrasound is adequate?Liver ultrasound and serum AFP.
A 55-year-old man with chronic HBV but no cirrhosis has a 1.8 cm lesion. MRI shows arterial phase hyperenhancement but no washout or capsule, and AFP is normal.
Which diagnosis is most likely?
Reason it through
What major imaging feature is present?Nonrim arterial phase hyperenhancement.
What required specificity-building feature is absent?There is no washout or enhancing capsule to complete a definitive pattern.
How should uncertainty be resolved?Use another diagnostic modality or selective biopsy after multidisciplinary review.
Arterial enhancement starts the HCC argument; it does not always finish it.
What major imaging feature is present?What required specificity-building feature is absent?
What major imaging feature is present?Nonrim arterial phase hyperenhancement.
What required specificity-building feature is absent?There is no washout or enhancing capsule to complete a definitive pattern.
How should uncertainty be resolved?Use another diagnostic modality or selective biopsy after multidisciplinary review.
A 64-year-old man has a solitary 2.5 cm HCC, Child-Pugh A liver function, no clinically significant portal hypertension, no vascular invasion, and an adequate future liver remnant.
Which treatment offers an appropriate curative strategy?
Reason it through
Is the tumor anatomically localized?Yes; it is solitary with no vascular or extrahepatic spread.
Can the liver tolerate resection?Preserved function, absent major portal hypertension, and adequate remnant support surgery.
What treatment class follows?Curative surgical resection.
Resection belongs to the tumor and the liver reserve together.
Is the tumor anatomically localized?Can the liver tolerate resection?
Is the tumor anatomically localized?Yes; it is solitary with no vascular or extrahepatic spread.
Can the liver tolerate resection?Preserved function, absent major portal hypertension, and adequate remnant support surgery.
What treatment class follows?Curative surgical resection.
A 57-year-old woman with decompensated cirrhosis has two HCC lesions measuring 2.2 cm and 2.8 cm, no vascular invasion, and no extrahepatic disease.
Which strategy best addresses both the cancer and the failing liver?
Reason it through
Does her tumor burden fit classic transplant limits?Yes; there are no more than three lesions and each is no larger than 3 cm.
Why is resection a poor fit?The decompensated liver lacks adequate reserve.
Which therapy treats tumor and field defect?Liver transplantation, often with bridging therapy while awaiting an organ.
Early HCC in a failing cirrhotic liver points toward transplant.
Does her tumor burden fit classic transplant limits?Why is resection a poor fit?
Does her tumor burden fit classic transplant limits?Yes; there are no more than three lesions and each is no larger than 3 cm.
Why is resection a poor fit?The decompensated liver lacks adequate reserve.
Which therapy treats tumor and field defect?Liver transplantation, often with bridging therapy while awaiting an organ.
A 66-year-old man with Child-Pugh A cirrhosis, ECOG performance status 0, no prior systemic therapy, and no immunotherapy contraindication has HCC with main portal vein tumor invasion and pulmonary metastases.
Which first-line plan correctly distinguishes induction from maintenance?
Reason it through
Which findings define advanced disease?Main portal vein tumor invasion and lung metastases.
Which newer first-line option fits this preserved-function patient?Nivolumab plus ipilimumab is FDA-approved first-line for unresectable or metastatic HCC.
How does its sequence change after induction?After at most four combination doses, ipilimumab stops and nivolumab continues as maintenance.
Induction is finite combination therapy; maintenance continues nivolumab alone.
Which findings define advanced disease?Which newer first-line option fits this preserved-function patient?
Which findings define advanced disease?Main portal vein tumor invasion and lung metastases.
Which newer first-line option fits this preserved-function patient?Nivolumab plus ipilimumab is FDA-approved first-line for unresectable or metastatic HCC.
How does its sequence change after induction?After at most four combination doses, ipilimumab stops and nivolumab continues as maintenance.
Rapid review
Three questions to check
What is the most appropriate diagnostic interpretation?
Imaging diagnosis of HCC in an at-risk patient. A lesion at least 1 cm with characteristic arterial hyperenhancement and washout on multiphasic CT or MRI can establish HCC noninvasively in an at-risk patient.
Does her etiology matter once cirrhosis is present?
No; cirrhosis from NASH is itself a surveillance indication.
Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.
